Literature DB >> 16186759

Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.

Aaron P Sarathy1, Sidney L Bourgeois, Gary G Goodell.   

Abstract

Bisphosphonates are commonly used in the management of bone diseases, such as osteoporosis and Paget's disease, and to prevent bone complications and to treat malignant hypercalcemia in certain types of cancer. Although this class of drugs has clear evidence of medical efficacy, there are an increasing number of reports of bisphosphonate-associated osteonecrosis of the jaws that have substantial implications for the patient and for the treating dentist. This case report reviews proposed possible mechanisms of bisphosphonate-associated osteonecrosis of the jaws and describes two case reports where nonsurgical and surgical root canal treatments were precipitating factors. Recommendations for prevention and treatment of the disease follow. Thorough history taking and timely consultation with the patient's oral surgeon and oncologist are emphasized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186759     DOI: 10.1097/01.don.0000182737.09980.2c

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  8 in total

1.  Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.

Authors:  Toshiyuki Yoneda; Hiroshi Hagino; Toshitsugu Sugimoto; Hiroaki Ohta; Shunji Takahashi; Satoshi Soen; Akira Taguchi; Satoru Toyosawa; Toshihiko Nagata; Masahiro Urade
Journal:  J Bone Miner Metab       Date:  2010-03-24       Impact factor: 2.626

Review 2.  [Osteonecrosis of the jaws by long term therapy with bisphosphonates].

Authors:  Jörn-Uwe Piesold; Bilal Al-Nawas; Knut A Grötz
Journal:  Mund Kiefer Gesichtschir       Date:  2006-09

Review 3.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 4.  Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.

Authors:  Franco Capsoni; Matteo Longhi; Roberto Weinstein
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

5.  Treatment of bisphosphonate related osteonecrosis following root canal therapy at the 1-year follow-up: report of two cases.

Authors:  Figen Kaptan; Meric Karapinar Kazandag; Ufuk Iseri
Journal:  Ther Clin Risk Manag       Date:  2013-12-02       Impact factor: 2.423

Review 6.  A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis.

Authors:  Roberto Sacco; Gianluca Sacco; Alessandro Acocella; Silvana Sale; Nicola Sacco; Edoardo Baldoni
Journal:  J Appl Oral Sci       Date:  2011-08       Impact factor: 2.698

7.  Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.

Authors:  Alexander Wick; Philipp Bankosegger; Sven Otto; Bettina Hohlweg-Majert; Timm Steiner; Florian Probst; Oliver Ristow; Christoph Pautke
Journal:  Clin Oral Investig       Date:  2021-11-23       Impact factor: 3.573

8.  A case of tooth fracture occurred upon medicating bisphosphonate for an elderly person: Preservation therapy and responses for Stage 0 of bisphosphonate-related osteonecrosis of jaw.

Authors:  Noriko Suzuki; Hitoshi Oguchi; Yu Yamauchi; Yasuyo Karube; Yukimi Suzuki; Noriyasu Hosoya
Journal:  Eur J Dent       Date:  2017 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.